Paris - Delayed Quote EUR

Sanofi (SAN.PA)

95.61

-0.69

(-0.72%)

At close: January 10 at 5:38:18 PM GMT+1

IGM Biosciences downgraded to Hold from Buy at Jefferies

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise and said it is evaluating internal options and strategic alternatives with the goal of maximizing value for its shareholders. Following the announcement, the firm removed clinical program revenue from its model and lowered its view of platform value to $50M, mostly related to the still-ongoing Sanofi (S

TipRanks 7 hours ago

IGMS

SNY

SNYNF
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.

Zacks yesterday

SNY
Sanofi reports positive results from trial of multiple myeloma drug candidate

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

Clinical Trials Arena yesterday

SNY
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma

On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab) subcutaneous formulation via an on-body delivery system (OBDS) versus weight-based dosed Sarclisa IV in combination with pomalidomide and dexamethasone (Pd) in adult patients with relapsed or refractory multiple myeloma. The trial demonstrated that Sarclisa SC, in combination with pomalidomide and dexamethasone (Pd), met its co-primary endpoints of non-infer

Benzinga 2 days ago

SNY
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDSOBDS is an alternative delivery method designed to improve the patient experience and currently availa

GlobeNewswire 2 days ago

SNY

SNYNF
Sanofi taps Alloy Therapeutics for CNS antisense drug development

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

Pharmaceutical Technology 3 days ago

SNY
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

The U.S. IPO market has seen an uptick amid falling interest rates, strong equity markets, and hopes of a friendlier regulatory environment under the incoming Trump administration. Maze's decision follows a strong 2024 for biotech companies, with firms such as Septerna and Bicara Therapeutics receiving a positive response from investors at their debut.

Reuters 4 days ago

SNY
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.

Zacks 4 days ago

DNLI

SNY
Sanofi Down 10% in 3 Months: How Should You Play the Stock?

SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock

Zacks 4 days ago

SNY
Drugmakers to raise US prices on over 250 medicines starting Jan. 1

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's Sanofi at the start of 2025, according to data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the drug price increases are below 10% - most well below. The median price increase of the drugs being hiked Jan. 1 is 4.5%, which is in line with the median for all price increases last year.

Reuters 11 days ago

PFE

SNY
The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and United-Guardian

ServiceNow, AMD, Sanofi, Team and United-Guardian are part of the Zacks top Analyst Blog.

Zacks 18 days ago

SNY

NOW

UG
Top Research Reports for ServiceNow, AMD & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW), Advanced Micro Devices, Inc. (AMD) and Sanofi (SNY), as well as two micro-cap stocks Team, Inc. (TISI) and United-Guardian, Inc. (UG).

Zacks 19 days ago

SNY

NOW

AMD
Why Is Sanofi (SNY) Among the Best European Dividend Stocks To Buy Now?

We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other European dividend stocks. Dividend payouts for MSCI Europe companies hit a record €407 billion in 2023, and they are set to grow even more […]

Insider Monkey 19 days ago

SNY
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.

Zacks 19 days ago

SNY

PCVX

PFE
SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines

Under the new agreement, Sanofi will make an upfront payment of $52.1m to SK bioscience.

Pharmaceutical Technology 19 days ago

SNY
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December 23, 2024. Sanofi and SK bioscience have entered into a new chap

GlobeNewswire 19 days ago

SNY

SNYNF
Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS

Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS). This designation follows positive results from the HERCULES phase 3 study, which showed tolebrutinib’s potential in delaying disability progression, addressing a significant unmet need in multiple sclerosis treatment. The designation aims to expedite the development of tolebrutinib, wh

TipRanks 21 days ago

SNY

SNYNF
Why Cytokinetics Stock Was a Nearly 5% Winner Today

This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics originally sold those rights to Corxel in 2020. Additionally, it can reap royalties on future sales of the drug in Greater China.

Motley Fool 22 days ago

CYTK

SNY
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.

Zacks 22 days ago

ABBV

PFE

SNY
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024. Jean-Paul Kress will hold his position for the remainder of Gilles Schnepp's term of office and his appointment will be subject to ratification at the next Ordinary Shareholders' Meeting of Sanofi. Jean-Paul Kress, M.D., serve

GlobeNewswire 23 days ago

SNY

SNYNF

Performance Overview

Return	SAN.PA	CAC 40
YTD	+2.65%	+1.61%
1-Year	+4.61%	+0.06%
3-Year	+21.28%	+2.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (SAN.PA)

IGM Biosciences downgraded to Hold from Buy at Jefferies

SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

Sanofi reports positive results from trial of multiple myeloma drug candidate

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Sanofi taps Alloy Therapeutics for CNS antisense drug development

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Sanofi Down 10% in 3 Months: How Should You Play the Stock?

Drugmakers to raise US prices on over 250 medicines starting Jan. 1

The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and United-Guardian

Top Research Reports for ServiceNow, AMD & Sanofi

Why Is Sanofi (SNY) Among the Best European Dividend Stocks To Buy Now?

Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Performance Overview